Gary Yeung, CFA is a life science executive (President, COO, CFO, and CBO), board member, advisor, and investor with extensive strategy, finance, business development, and operations experience in forming and building biotech companies and developing novel therapies.
Gary has raised over $570M ($370M as CFO and $200M as an advisor and board member) while forming and building multiple successful biotech companies: Xilis, Erasca (NASDAQ: ERAS), NiKang, Guardant Health (NASDAQ: GH), and Annexon Biosciences (NASDAQ: ANNX). He has led organizations engaged in filing 42 INDs, and led teams that launched multiple FDA-approved treatments at Genentech. Earlier in his career, he worked in management consulting at McKinsey and operations leadership at GE.
Gary holds a B.S. in Chemical Engineering from the University of California, Berkeley and an MBA from University of California, Los Angeles. He is a Chartered Financial Analyst (CFA).
Current role